Lipoprotein apheresis andPCSK9inhibitors for severe familial hypercholesterolaemia: Experience from Australia and New Zealand
Michael M Page, Elif Ekinci, John R Burnett, Amanda J Hooper, Nicola Reid, Warrick Bishop, Chris M Florkowski, Russell Scott, Richard C O'Brien, Gerald F Watts
JOURNAL OF CLINICAL APHERESIS | WILEY | Published : 2021
Introduction Severe familial hypercholesterolaemia (FH) causes premature disability and death due to atherosclerotic cardiovascular disease and is refractory to standard lipid‐lowering therapies. Lipoprotein apheresis (LA) has long been a standard of care for patients with severe FH, but is invasive, expensive and time‐consuming for patients and their caregivers. Newer drug therapies, including the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, may reduce the need for LA. Materials and methods We audited the records of 16 patients (eight homozygous, eight heterozygous) treated with LA in Australia and New Zealand, 14 of whom subsequently commenced PCSK9 inhibitor therapy...View full abstract
The authors wish to thank our patients for participating in this study, and the clinical staff involved in providing apheresis including: Dr Krishna Badami and team (Christchurch Therapeutic Apheresis, Christchurch, New Zealand); Dr Daniela Zantomio and Ms Pina Polidano, (Austin Health, Heidelberg, Australia); Dr Anna Johnston and Ms Bronwen Neely (Royal Hobart Hospital, Hobart, Australia); C/Prof Michael Leahy and Dr Ben Carnley (Royal Perth Hospital, Perth, Australia); and Dr Paul Cannell and Mr Justin Gerace (Fiona Stanley Hospital, Murdoch, Australia). MMP was supported by an Australian Government Research Training Program (RTP) Scholarship.